199 related articles for article (PubMed ID: 20534173)
21. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
22. Temporal evolution of soluble Fas and Fas ligand in patients with orthotopic liver transplantation.
Wang Y; Liu Y; Han R; Yang J; Zhu Z; Zhang Y; Yao Z; Gao W; Shen Z
Cytokine; 2008 Mar; 41(3):240-3. PubMed ID: 18267366
[TBL] [Abstract][Full Text] [Related]
23. Circulating soluble Fas ligand correlates with disease activity in Graves' hyperthyroidism.
Wang CY; Zhong WB; Chang TC; Tsai YF
Metabolism; 2002 Jun; 51(6):769-73. PubMed ID: 12037733
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of soluble Fas and Fas ligand in pregnant women who smoke.
Hasan S; Alshaikh B; Yusuf K
Am J Reprod Immunol; 2021 Jun; 85(6):e13382. PubMed ID: 33247994
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of soluble concentration Fas and Fas ligand in maternal and cord blood 3rd trimester of pregnancy.
Karowicz-Bilińska A; Kowalska-Koprek U; Estemberg D; Sikora-Szubert A
Ginekol Pol; 2018; 89(3):142-146. PubMed ID: 29664549
[TBL] [Abstract][Full Text] [Related]
26. Circulating soluble Fas ligand in patients with gastric carcinoma.
Tsutsumi S; Kuwano H; Shimura T; Morinaga N; Mochiki E; Asao T
Cancer; 2000 Dec; 89(12):2560-4. PubMed ID: 11135216
[TBL] [Abstract][Full Text] [Related]
27. Examination of soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with burns.
Yamada Y; Endo S; Nakae H; Makabe H; Sato N; Wakabayashi G; Kitamura M; Inada K; Sato S
Burns; 2003 Dec; 29(8):799-802. PubMed ID: 14636754
[TBL] [Abstract][Full Text] [Related]
28. Increased serum levels of soluble Fas in progressive B-CLL.
Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415
[TBL] [Abstract][Full Text] [Related]
29. Expression of soluble Fas and soluble FasL in human nucleus pulposus cells.
Sun Z; Wan ZY; Liu ZH; Guo YS; Yin JB; Duan CG; Gao Y; Li T; Wang HQ; Luo ZJ
Int J Clin Exp Pathol; 2013; 6(8):1567-73. PubMed ID: 23923075
[TBL] [Abstract][Full Text] [Related]
30. Serum apoptosis markers in HIV-infected patients with human herpesvirus type 8 and herpes simplex virus type 2 co-infection.
Dakovic Rode O; Markotic A; Kujundzic Tiljak M; Zidovec Lepej S; Begovac J
Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3303-8. PubMed ID: 22837067
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.
Wang XZ; Chen XC; Chen YX; Zhang LJ; Li D; Chen FL; Chen ZX; Chen HY; Tao QM
World J Gastroenterol; 2003 Dec; 9(12):2671-5. PubMed ID: 14669310
[TBL] [Abstract][Full Text] [Related]
32. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
Adly AA; Ismail EA; Andrawes NG; Mahmoud MM; Eladawy R
Cytokine; 2016 Mar; 79():52-8. PubMed ID: 26765484
[TBL] [Abstract][Full Text] [Related]
33. Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance.
Cosson E; Bringuier AF; Paries J; Guillot R; Vaysse J; Attali JR; Feldmann G; Valensi P
Diabetes Metab; 2005 Feb; 31(1):47-54. PubMed ID: 15803113
[TBL] [Abstract][Full Text] [Related]
34. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis.
Sugita S; Taguchi C; Takase H; Sagawa K; Sueda J; Fukushi K; Hikita N; Watanabe T; Itoh K; Mochizuki M
Br J Ophthalmol; 2000 Oct; 84(10):1130-4. PubMed ID: 11004098
[TBL] [Abstract][Full Text] [Related]
35. Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery.
Kawahito K; Misawa Y; Fuse K
Artif Organs; 2000 Aug; 24(8):628-31. PubMed ID: 10971250
[TBL] [Abstract][Full Text] [Related]
36. Serum chemokine ligand 5 (CCL5/RANTES) level might be utilized as a predictive marker of tumor behavior and disease prognosis in patients with gastric adenocarcinoma.
Sima AR; Sima HR; Rafatpanah H; Hosseinnezhad H; Ghaffarzadehgan K; Valizadeh N; Mehrabi Bahar M; Hakimi HR; Masoom A; Noorbakhsh A; Razavi Satvati N; Raziee HR
J Gastrointest Cancer; 2014 Dec; 45(4):476-80. PubMed ID: 25301002
[TBL] [Abstract][Full Text] [Related]
37. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
38. Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.
El-Sarha AI; Magour GM; Zaki SM; El-Sammak MY
Pathol Oncol Res; 2009 Jun; 15(2):241-50. PubMed ID: 19015953
[TBL] [Abstract][Full Text] [Related]
39. Significance of Fas and Fas ligand in tuberculous lymphadenitis.
Mustafa T; Mogga SJ; Mfinanga SG; Mørkve O; Sviland L
Immunology; 2005 Feb; 114(2):255-62. PubMed ID: 15667570
[TBL] [Abstract][Full Text] [Related]
40. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Kuwano K; Maeyama T; Inoshima I; Ninomiya K; Hagimoto N; Yoshimi M; Fujita M; Nakamura N; Shirakawa K; Hara N
Respirology; 2002 Mar; 7(1):15-21. PubMed ID: 11896896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
